Charles River Laboratories International, Inc. (CRL)

Market Cap	10.81B +42.5%
Revenue (ttm)	4.03B +0.1%
Net Income	-184.65M
EPS	-3.76
Shares Out	48.17M
PE Ratio	n/a
Forward PE	19.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	571,989
Open	224.94
Previous Close	229.16
Day's Range	222.67 - 228.53
52-Week Range	144.26 - 237.86
Beta	1.40
Analysts	Buy
Price Target	230.93 (+2.93%)
Earnings Date	Aug 5, 2026

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 19,700
• Stock Exchange: NYSE
• Ticker Symbol: CRL
• Website: https://www.criver.com

Analyst Summary

According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $230.93, which is an increase of 2.93% from the latest price.

Price Target

$230.93

(2.93% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 17, 2026

Data Sources Report a data error